肺转移瘤立体定向放疗:RSSearch®患者登记研究经验
基于RSSearch®登记中447例可评估生存的肺转移瘤患者,SBRT中位OS为26个月,1年、3年和5年OS分别为74.1%、33.3%和21.8%;BED≥100Gy10者3年LC为77.1%,优于BED<100Gy10的45%(p=0.01);肿瘤体积<11 cc者LC和OS更优。
要点
- 肺转移瘤SBRT中位OS 26个月,中位LC 53个月。
- BED≥100Gy10者3年LC 77.1%,优于BED<100Gy10的45%(p=0.01)。
- 肿瘤体积<11 cc者LC和OS优于更大体积者。
核心结论
- 根据RSSearch®登记数据,采用BED≥100Gy10的SBRT治疗肺转移瘤可获得良好的OS和LC。
- 小体积肺转移瘤(<11 cc)接受BED≥100Gy10的SBRT时LC和OS更好。
研究设计与样本
- 患者来自30个学术和社区中心,2004年4月至2015年7月接受SBRT,排除既往接受手术、放疗或射频消融者。
- 所有剂量转换为蒙特卡洛等效剂量及BED Gy10进行剂量效应分析。
主要发现
- 全组中位OS为26个月,1年、3年和5年OS分别为74.1%、33.3%和21.8%。
- 全组中位LC为53个月,1年、3年和5年LC分别为80.4%、58.9%和46.3%。
- 不同原发组织学类型间LC无差异(p=0.49)。
- BED≥100Gy10者3年LC为77.1%,BED<100Gy10者为45%(p=0.01)。
- 肿瘤体积<11 cc、11-27 cc和>27 cc的2年LC分别为72.9%、64.2%和45.6%,2年OS分别为62.4%、60.9%和46.2%(p=0.0023)。
关键数值与推荐
- 中位剂量50 Gy(范围25/75%:48-54 Gy),中位3次(范围25/75%:3-5次),中位BED 100Gy10(范围25/75%:81-136 Gy10)。
- BED≥100Gy10组3年LC 77.1%,BED<100Gy10组45%(p=0.01)。
- 肿瘤体积<11 cc、11-27 cc和>27 cc的2年LC分别为72.9%、64.2%和45.6%(p=0.005)。
- BED≥100Gy10亚组中,体积<11 cc、11-27 cc和>27 cc的2年LC分别为82.8%、58.9%和68.6%(p=0.0244),2年OS分别为66.0%、58.8%和28.5%(p=0.0081)。
临床怎么用
- 肺转移瘤SBRT应尽量使BED≥100Gy10以改善局部控制。
- 肿瘤体积<11 cc者接受BED≥100Gy10的SBRT可获得更好LC和OS。
- 原发肿瘤类型不影响LC,但头颈和乳腺癌患者中位OS较长(分别为37和32个月)。
局限性
- 为登记研究,非随机对照,存在选择偏倚。
- 作者指出需更大样本量研究评估不同肿瘤类型间的差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To report overall survival and local control for patients identified in the RSSearch® Patient Registry with metastatic cancer to the lung treated with SBRT. METHODS: Seven hundred two patients were identified with lung metastases in the RSSearch® Registry. Of these patients, 577 patients had SBRT dose and fractionation information available. Patients were excluded if they received prior surgery, radiation, or radiofrequency ablation to the SBRT treated area. Between April 2004-July 2015, 447 patients treated with SBRT at 30 academic and community-based centers were evaluable for overall survival (OS). Three hundred four patients with 327 lesions were evaluable for local control (LC). All doses were converted to Monte Carlo equivalents and subsequent BED Gy10 for dose response analysis. RESULTS: Median age was 69 years (range, 18-93 years). Median Karnofsky performance status (KPS) was 90 (range 25/75% 80-100). 49.2% of patients had prior systemic therapy. Median metastasis volume was 10.58 cc (range 25/75% 3.7-25.54 cc). Site of primary tumor included colorectal (25.7%), lung (16.6%), head and neck (11.4%), breast (9.2%), kidney (8.1%), skin (6.5%) and other (22.1%). Median dose was 50 Gy (range 25/75% 48-54) delivered in 3 fractions (range 25/75% 3-5) with a median BED of 100Gy10 (range 25/75% 81-136). Median OS for the entire group was 26 months, with actuarial 1-, 3-, and 5-year OS of 74.1%, 33.3, and 21.8%, respectively. Patients with head and neck and breast cancers had longer median OS of 37 and 32 months respectively, compared to colorectal (30 months) and lung (26 months) which corresponded to 3-year actuarial OS of 51.8 and 47.9% for head and neck and breast respectively, compared to 35.8% for colorectal and 31.2% for lung. The median LC for all patients was 53 months, with actuarial 1-, 3-, and 5-year LC rates of 80.4, 58.9, and 46.3%, respectively. There was no difference in LC by primary histologic type (p = 0.49). Improved LC was observed for lung metastases that received SBRT doses of BED ≥100Gy10 with 3-year LC rate of 77.1% compared to 45% for lung metastases treated with BED < 100Gy10 (p = 0.01). Smaller tumor volumes (<11 cc) had improved LC compared to tumor volumes > 11 cc. (p = 0.005) Two-year LC rates for tumor volumes < 11 cc, 11-27 cc and > 27 cc were 72.9, 64.2 and 45.6%, respectively. This correlated with improved OS with 2-year OS rates of 62.4, 60.9 and 46.2% for tumor volumes < 11 cc, 11-27 cc and > 27 cc, respectively (p = 0.0023). In a subset of patients who received BED ≥100Gy10, 2-year LC rates for tumor volumes < 11 cc, 11-27 cc and > 27 cc were 82.8, 58.9 and 68.6%, respectively (p = 0.0244), and 2-year OS rates were 66.0, 58.8 and 28.5%, respectively (p = 0.0081). CONCLUSION: Excellent OS and LC is achievable with SBRT utilizing BED ≥100Gy10 for lung metastases according to the RSSearch® Registry data. Patients with small lung metastases (volumes < 11 cc) had better LC and OS when using SBRT doses of BED ≥100Gy10. Further studies to evaluate a difference, if any, between various tumor types will require a larger number of patients.
引用
- Ricco A, Davis J, Rate W, et al. Lung metastases treated with stereotactic body radiotherapy: the RSSearch® patient Registry's experience. Radiat Oncol. 2017. PMID: 28143558. doi:10.1186/s13014-017-0773-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。